FDG and Non-FDG Radiopharmaceuticals for PET Imaging in Invasive Lobular Breast Carcinoma
Invasive lobular cancer (ILC) is the second most frequent histological type of breast cancer (BC) and includes a heterogeneous spectrum of diseases with unique characteristics, especially the infiltrative growth pattern and metastatic spread. [<sup>18</sup>F]fluoro-2-deoxy-D-glucose posi...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/11/5/1350 |
| _version_ | 1827741965922336768 |
|---|---|
| author | Laura Gilardi Lighea Simona Airò Farulla Giuseppe Curigliano Giovanni Corso Maria Cristina Leonardi Francesco Ceci |
| author_facet | Laura Gilardi Lighea Simona Airò Farulla Giuseppe Curigliano Giovanni Corso Maria Cristina Leonardi Francesco Ceci |
| author_sort | Laura Gilardi |
| collection | DOAJ |
| description | Invasive lobular cancer (ILC) is the second most frequent histological type of breast cancer (BC) and includes a heterogeneous spectrum of diseases with unique characteristics, especially the infiltrative growth pattern and metastatic spread. [<sup>18</sup>F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) is extensively used in oncology and BC patient evaluation. Its role in ILCs is considered suboptimal due to its low FDG avidity. Therefore, ILCs could benefit from molecular imaging with non-FDG tracers that target other specific pathways, contributing to precision medicine. This narrative review aims to summarize the current literature on the use of FDG-PET/CT in ILC and to discuss future opportunities given by the development of innovative non-FDG radiotracers. |
| first_indexed | 2024-03-11T03:54:39Z |
| format | Article |
| id | doaj.art-52bf8774b4d148599d9082b18075b5bf |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-11T03:54:39Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-52bf8774b4d148599d9082b18075b5bf2023-11-18T00:35:45ZengMDPI AGBiomedicines2227-90592023-05-01115135010.3390/biomedicines11051350FDG and Non-FDG Radiopharmaceuticals for PET Imaging in Invasive Lobular Breast CarcinomaLaura Gilardi0Lighea Simona Airò Farulla1Giuseppe Curigliano2Giovanni Corso3Maria Cristina Leonardi4Francesco Ceci5Division of Nuclear Medicine, IEO European Institute of Oncology IRCCS, 20141 Milan, ItalyDivision of Nuclear Medicine, IEO European Institute of Oncology IRCCS, 20141 Milan, ItalyDepartment of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, ItalyDepartment of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, ItalyDivision of Radiotherapy, IEO European Institute of Oncology IRCCS, 20141 Milan, ItalyDivision of Nuclear Medicine, IEO European Institute of Oncology IRCCS, 20141 Milan, ItalyInvasive lobular cancer (ILC) is the second most frequent histological type of breast cancer (BC) and includes a heterogeneous spectrum of diseases with unique characteristics, especially the infiltrative growth pattern and metastatic spread. [<sup>18</sup>F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) is extensively used in oncology and BC patient evaluation. Its role in ILCs is considered suboptimal due to its low FDG avidity. Therefore, ILCs could benefit from molecular imaging with non-FDG tracers that target other specific pathways, contributing to precision medicine. This narrative review aims to summarize the current literature on the use of FDG-PET/CT in ILC and to discuss future opportunities given by the development of innovative non-FDG radiotracers.https://www.mdpi.com/2227-9059/11/5/1350PET/CTlobular breast carcinomaFDGFESFAPi |
| spellingShingle | Laura Gilardi Lighea Simona Airò Farulla Giuseppe Curigliano Giovanni Corso Maria Cristina Leonardi Francesco Ceci FDG and Non-FDG Radiopharmaceuticals for PET Imaging in Invasive Lobular Breast Carcinoma Biomedicines PET/CT lobular breast carcinoma FDG FES FAPi |
| title | FDG and Non-FDG Radiopharmaceuticals for PET Imaging in Invasive Lobular Breast Carcinoma |
| title_full | FDG and Non-FDG Radiopharmaceuticals for PET Imaging in Invasive Lobular Breast Carcinoma |
| title_fullStr | FDG and Non-FDG Radiopharmaceuticals for PET Imaging in Invasive Lobular Breast Carcinoma |
| title_full_unstemmed | FDG and Non-FDG Radiopharmaceuticals for PET Imaging in Invasive Lobular Breast Carcinoma |
| title_short | FDG and Non-FDG Radiopharmaceuticals for PET Imaging in Invasive Lobular Breast Carcinoma |
| title_sort | fdg and non fdg radiopharmaceuticals for pet imaging in invasive lobular breast carcinoma |
| topic | PET/CT lobular breast carcinoma FDG FES FAPi |
| url | https://www.mdpi.com/2227-9059/11/5/1350 |
| work_keys_str_mv | AT lauragilardi fdgandnonfdgradiopharmaceuticalsforpetimagingininvasivelobularbreastcarcinoma AT ligheasimonaairofarulla fdgandnonfdgradiopharmaceuticalsforpetimagingininvasivelobularbreastcarcinoma AT giuseppecurigliano fdgandnonfdgradiopharmaceuticalsforpetimagingininvasivelobularbreastcarcinoma AT giovannicorso fdgandnonfdgradiopharmaceuticalsforpetimagingininvasivelobularbreastcarcinoma AT mariacristinaleonardi fdgandnonfdgradiopharmaceuticalsforpetimagingininvasivelobularbreastcarcinoma AT francescoceci fdgandnonfdgradiopharmaceuticalsforpetimagingininvasivelobularbreastcarcinoma |